title: Role of cyclooxygenase activation and prostaglandins in antigen-induced excitability changes of bronchial parasympathetic ganglia neurons.
abstract: In vitro antigen challenge has multiple effects on the excitability of guinea pig bronchial parasympathetic ganglion neurons, including depolarization, causing phasic neurons to fire with a repetitive action potential pattern and potentiating synaptic transmission. In the present study, guinea pigs were passively sensitized to the antigen ovalbumin. After sensitization, the bronchi were prepared for in vitro electrophysiological intracellular recording of parasympathetic ganglia neurons to investigate the contribution of cyclooxygenase activation and prostanoids on parasympathetic nerve activity. Cyclooxygenase inhibition with either indomethacin or piroxicam before in vitro antigen challenge blocked the change in accommodation. These cyclooxygenase inhibitors also blocked the release of prostaglandin D(2) (PGD(2)) from bronchial tissue during antigen challenge. We also determined that PGE(2) and PGD(2) decreased the duration of the action potential after hyperpolarization, whereas PGF(2alpha) potentiated synaptic transmission. Thus prostaglandins released during antigen challenge have multiple effects on the excitability of guinea pig bronchial parasympathetic ganglia neurons, which may consequently affect the output from these neurons and thereby alter parasympathetic tone in the lower airways.
authors.affiliation: Department of Anatomy, Physiology, and Cell Biology, School of Veterinary Medicine, University of California, Davis, 95616, USA.
authors.forename: Radhika
authors.initials: R
authors.lastname: Kajekar
authors.forename: Bradley J
authors.initials: BJ
authors.lastname: Undem
authors.forename: Allen C
authors.initials: AC
authors.lastname: Myers
mesh_terms: D000200:Action Potentials / Q000187:drug effects; D000818:Animals; D001249:Asthma / Q000378:metabolism / Q000503:physiopathology; D001980:Bronchi / Q000294:innervation*; D016084:Bronchoconstriction / Q000502:physiology; D016861:Cyclooxygenase Inhibitors / Q000494:pharmacology; D015237:Dinoprost / Q000378:metabolism / Q000494:pharmacology; D015232:Dinoprostone / Q000378:metabolism / Q000494:pharmacology; D019706:Excitatory Postsynaptic Potentials / Q000187:drug effects; D005726:Ganglia, Parasympathetic / Q000502:physiology*; D006168:Guinea Pigs; D007213:Indomethacin / Q000494:pharmacology; D008297:Male; D010047:Ovalbumin / Q000494:pharmacology; D010894:Piroxicam / Q000494:pharmacology; D015230:Prostaglandin D2 / Q000378:metabolism / Q000494:pharmacology; D011451:Prostaglandin-Endoperoxide Synthases / Q000378:metabolism*; D011453:Prostaglandins / Q000378:metabolism* / Q000494:pharmacology; D009435:Synaptic Transmission / Q000502:physiology
chemical_list: D016861:Cyclooxygenase Inhibitors; D011453:Prostaglandins; D010894:Piroxicam; D010047:Ovalbumin; D015237:Dinoprost; D011451:Prostaglandin-Endoperoxide Synthases; D015232:Dinoprostone; D015230:Prostaglandin D2; D007213:Indomethacin